Skannex AS, Oslo, Norway (“Skannex”) and Abingdon Health Limited (“Abingdon”), York, UK and jointly announce that both parties have entered into a co-marketing agreement to provide lateral flow assay and reader development and manufacturing solutions to contract customers.
Under the agreement, Skannex will be Abingdon Health’s preferred partner for the supply of hand-held reader instrumentation and Abingdon will be Skannex’s preferred partner for lateral flow assay development and manufacturing. Both parties will work collaboratively on providing customers with integrated assay and reader development solutions.
Abingdon’s core expertise lies in the development, manufacturing and commercialisation of rapid lateral flow immunoassay diagnostics and reader systems. The Company provides contract services across all diagnostic sectors including healthcare, veterinary, agri-food, and environmental. In addition to this Abingdon has developed a range of rapid tests in the area of hematology-oncology, the first product Seralite®– FLC was launched in January 2016, and is the world’s first rapid diagnostic device in multiple myeloma.
Skannex’s core expertise lies in the development, manufacturing and commercialisation of handheld and desktop reader systems for rapid tests. All readers are enabled by Skannex’ proprietary software for image capture and analysis. The flexibility and solidity of the Skannex reader software fulfill the demand from their lateral flow test customers to go to market with a high quality diagnostic system.
The Company has successful customers in all relevant market segments such as Human IVD, Drug of Abuse, Veterinary and Food Toxicity testing.
Commenting on the Agreement
Chris Yates, CEO of Abingdon Health said:
“We are focused on providing our contract customers with the broadest range of reader instrumentation and Skannex are a clear market leader in the provision of hand-held reader technology. Therefore, we are pleased to be able to offer our contract customers the opportunity to integrate the development of assay and reader solutions that incorporate the skills, technology and experience of both Abingdon Health and Skannex”.
Siri Stabel Olsen, CEO of Skannex said:
“The co-marketing agreement entered into with Abingdon Health is a significant add-on to Skannex customers who seek rapid test development and manufacturing expertise tailored for Skannex reader platforms. With the market moving more and more towards decentralised rapid testing this collaboration will give the marketers and end users the quality and user friendliness they deserve.”
Phone Number: +44 (0)1904 406082